Expertise in
22
conditions

Dr. Parvez S. Mantry

Hepatology
Medhealth
3000 Blackburn St, Suite 130, 
Dallas, TX 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Medhealth
3000 Blackburn St, Suite 130, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Parvez Mantry is a Hepatologist in Dallas, Texas. Dr. Mantry is highly rated in 22 conditions, according to our data. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Liver Failure, Hepatitis, Liver Transplant, and Endoscopy. Dr. Mantry is currently accepting new patients.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in TX
Hospital Affiliations
Christus Mother Frances Hospital
Methodist Dallas Medical Center
Methodist Richardson Medical Center
Bsa Hospital
Hunt Regional Medical Center
Languages Spoken
English
Hindi
Marathi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

MEDHEALTH
3000 Blackburn St, Suite 130, Dallas, TX 75204
Other Locations
MEDHEALTH
613 S Hwy 78, Suite 200, Wylie, TX 75098
MEDHEALTH
5040 Kinsey Dr, Suite 100, Tyler, TX 75703
MEDHEALTH
5300 W Plano Pkwy, Suite 300, Plano, TX 75093
MEDHEALTH
2821 E President G Bush Hwy, Richardson, TX 75082
MEDHEALTH
5224 S State Hwy 360, Grand Prairie, TX 75052
MEDHEALTH
6833 Plum Creek Dr, Amarillo, TX 79124
MEDHEALTH
1441 N Beckley Ave, Dallas, TX 75203

Additional Areas of Focus

Dr. Mantry has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Combination product
Study Phase: Not Applicable
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 06, 2022
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 4
A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
Enrollment Status: Completed
Publish Date: November 11, 2021
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Enrollment Status: Withdrawn
Publish Date: August 30, 2021
Intervention Type: Drug, Device
Study Phase: Early Phase 1
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 14 Less Clinical Trials

44 Total Publications

Letter: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy.
Letter: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy.
Journal: Alimentary pharmacology & therapeutics
Published: March 20, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Marlyn J. Mayo
Hepatology
Expertise in
19
conditions
Dr. Marlyn J. Mayo
Hepatology

University Of Texas Southwestern Medical Center At Dallas

2001 Inwood Rd, 
Dallas, TX 
 (2.9 mi)
Languages Spoken:
English
See accepted insurances

Marlyn Mayo is a Hepatologist in Dallas, Texas. Dr. Mayo is highly rated in 19 conditions, according to our data. Her top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Cirrhosis, Melioidosis, and Liver Transplant.

Expertise in
19
conditions
Dr. Amit G. Singal
Hepatology
Expertise in
19
conditions
Dr. Amit G. Singal
Hepatology

University Of Texas Southwestern Medical Center At Dallas

5151 Maple Ave, 
Dallas, TX 
 (2.1 mi)
214-266-3333
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amit Singal is a Hepatologist in Dallas, Texas. Dr. Singal is highly rated in 19 conditions, according to our data. His top areas of expertise are Liver Cancer, Cirrhosis, Hepatitis C, Liver Transplant, and Colonoscopy.

Expertise in
13
conditions
Dr. Robert S. Rahimi
Hepatology | Gastroenterology
Expertise in
13
conditions
Dr. Robert S. Rahimi
Hepatology | Gastroenterology

Healthtexas Provider Network

4001 Worth St, 
Dallas, TX 
 (1.6 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Rahimi is a Hepatologist and a Gastroenterologist in Dallas, Texas. Dr. Rahimi is highly rated in 13 conditions, according to our data. His top areas of expertise are Liver Failure, Esophageal Varices, Cirrhosis, Liver Transplant, and Hepato-Pancreato-Biliary Surgery. Dr. Rahimi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mantry's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 9 Advanced Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile